BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 18785974)

  • 1. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment.
    Pearson T; Shultz LD; Miller D; King M; Laning J; Fodor W; Cuthbert A; Burzenski L; Gott B; Lyons B; Foreman O; Rossini AA; Greiner DL
    Clin Exp Immunol; 2008 Nov; 154(2):270-84. PubMed ID: 18785974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.
    Pino S; Brehm MA; Covassin-Barberis L; King M; Gott B; Chase TH; Wagner J; Burzenski L; Foreman O; Greiner DL; Shultz LD
    Methods Mol Biol; 2010; 602():105-17. PubMed ID: 20012395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.
    Shultz LD; Lyons BL; Burzenski LM; Gott B; Chen X; Chaleff S; Kotb M; Gillies SD; King M; Mangada J; Greiner DL; Handgretinger R
    J Immunol; 2005 May; 174(10):6477-89. PubMed ID: 15879151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation.
    Brehm MA; Cuthbert A; Yang C; Miller DM; DiIorio P; Laning J; Burzenski L; Gott B; Foreman O; Kavirayani A; Herlihy M; Rossini AA; Shultz LD; Greiner DL
    Clin Immunol; 2010 Apr; 135(1):84-98. PubMed ID: 20096637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene.
    King M; Pearson T; Shultz LD; Leif J; Bottino R; Trucco M; Atkinson MA; Wasserfall C; Herold KC; Woodland RT; Schmidt MR; Woda BA; Thompson MJ; Rossini AA; Greiner DL
    Clin Immunol; 2008 Mar; 126(3):303-14. PubMed ID: 18096436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells.
    Covassin L; Jangalwe S; Jouvet N; Laning J; Burzenski L; Shultz LD; Brehm MA
    Clin Exp Immunol; 2013 Dec; 174(3):372-88. PubMed ID: 23869841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells.
    Shultz LD; Lang PA; Christianson SW; Gott B; Lyons B; Umeda S; Leiter E; Hesselton R; Wagar EJ; Leif JH; Kollet O; Lapidot T; Greiner DL
    J Immunol; 2000 Mar; 164(5):2496-507. PubMed ID: 10679087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.
    Ito M; Hiramatsu H; Kobayashi K; Suzue K; Kawahata M; Hioki K; Ueyama Y; Koyanagi Y; Sugamura K; Tsuji K; Heike T; Nakahata T
    Blood; 2002 Nov; 100(9):3175-82. PubMed ID: 12384415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice.
    Ishikawa F; Yasukawa M; Lyons B; Yoshida S; Miyamoto T; Yoshimoto G; Watanabe T; Akashi K; Shultz LD; Harada M
    Blood; 2005 Sep; 106(5):1565-73. PubMed ID: 15920010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2rgammanull Ins2Akita mice.
    Brehm MA; Bortell R; Diiorio P; Leif J; Laning J; Cuthbert A; Yang C; Herlihy M; Burzenski L; Gott B; Foreman O; Powers AC; Greiner DL; Shultz LD
    Diabetes; 2010 Sep; 59(9):2265-70. PubMed ID: 20570944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrahepatic transplantation of cord blood CD34+ cells into newborn NOD/SCID-IL2Rγ(null) mice allows efficient multi-organ and multi-lineage hematopoietic engraftment without accessory cells.
    Navarro-Montero O; Romero-Moya D; Montes R; Ramos-Mejía V; Bueno C; Real PJ; Menendez P
    Clin Immunol; 2012 Nov; 145(2):89-91. PubMed ID: 22964517
    [No Abstract]   [Full Text] [Related]  

  • 12. Cellular-based therapies to prevent or reduce thrombocytopenia.
    Pineault N; Boyer L
    Transfusion; 2011 Nov; 51 Suppl 4():72S-81S. PubMed ID: 22074630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human nasal polyp microenvironments maintained in a viable and functional state as xenografts in NOD-scid IL2rgamma(null) mice.
    Bernstein JM; Brooks SP; Lehman HK; Pope L; Sands A; Shultz LD; Bankert RB
    Ann Otol Rhinol Laryngol; 2009 Dec; 118(12):866-75. PubMed ID: 20112521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
    Carreno BM; Garbow JR; Kolar GR; Jackson EN; Engelbach JA; Becker-Hapak M; Carayannopoulos LN; Piwnica-Worms D; Linette GP
    Clin Cancer Res; 2009 May; 15(10):3277-86. PubMed ID: 19447870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses.
    Watanabe S; Terashima K; Ohta S; Horibata S; Yajima M; Shiozawa Y; Dewan MZ; Yu Z; Ito M; Morio T; Shimizu N; Honda M; Yamamoto N
    Blood; 2007 Jan; 109(1):212-8. PubMed ID: 16954502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humanized SCID mouse models for biomedical research.
    Pearson T; Greiner DL; Shultz LD
    Curr Top Microbiol Immunol; 2008; 324():25-51. PubMed ID: 18481451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of Immunodeficient Mice Bearing Human Immune Systems by the Engraftment of Hematopoietic Stem Cells.
    Hasgur S; Aryee KE; Shultz LD; Greiner DL; Brehm MA
    Methods Mol Biol; 2016; 1438():67-78. PubMed ID: 27150084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient xenoengraftment in severe immunodeficient NOD/Shi-scid IL2rγnull mice is attributed to a lack of CD11c+B220+CD122+ cells.
    Ito R; Katano I; Ida-Tanaka M; Kamisako T; Kawai K; Suemizu H; Aiso S; Ito M
    J Immunol; 2012 Nov; 189(9):4313-20. PubMed ID: 23018460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of human short-term repopulating cell (STRC) engraftment in NOD/SCID mice by host CD122+ cells.
    Shultz LD; Banuelos SJ; Leif J; Appel MC; Cunningham M; Ballen K; Burzenski L; Greiner DL
    Exp Hematol; 2003 Jun; 31(6):551-8. PubMed ID: 12829032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Generation of a new strain of NOD/SCID/IL2Rγ
    Liu YC; Chen Q; Yang XL; Tang QS; Yao KT; Xu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jun; 38(6):639-646. PubMed ID: 29997084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.